Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECT-001-expanded Cord Blood in High-risk Acute Leukemia/MDS
NCT03913026Phase 2Active, not recruiting
- Start
- Apr 2019
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dorocubicel in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). Primary endpoints: Transplant Related Mortality at 1 year, Relapse Free Survival at 2 years and 1 more. Started Apr 2019; status: active, not recruiting.
02
Drugs
dorocubicel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03913026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913026.